{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=19&state=Florida", "query": { "state": "Florida", "city": "Orlando", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 6846, "total_pages": 685, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=20&state=Florida&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=18&state=Florida&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T00:17:00.720Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03393013", "title": "A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lupus Nephritis", "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "KZR-616", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kezar Life Sciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 69, "start_date": "2018-02-20", "completion_date": "2022-08-04", "has_results": true, "last_update_posted_date": "2025-11-18", "last_synced_at": "2026-10-31T00:17:00.720Z", "location_count": 17, "location_summary": "Los Angeles, California • Upland, California • Miami, Florida + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03393013" }, { "nct_id": "NCT05222880", "title": "Evaluation of a Daily Disposable Silicone Hydrogel Multifocal Contact Lens in Myopes and Hyperopes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Visual Acuity" ], "interventions": [ { "name": "JJVC Investigational Multifocal Contact Lenses manufactured in senofilcon A C3", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Johnson & Johnson Vision Care, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "40 Years to 70 Years" }, "enrollment_count": 140, "start_date": "2022-01-06", "completion_date": "2022-02-28", "has_results": true, "last_update_posted_date": "2023-04-13", "last_synced_at": "2026-10-31T00:17:00.720Z", "location_count": 12, "location_summary": "Jacksonville, Florida • Maitland, Florida • Tallahassee, Florida + 8 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Maitland", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "Pittsburg", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05222880" }, { "nct_id": "NCT00822120", "title": "S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Nonneoplastic Condition" ], "interventions": [ { "name": "bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "ABVD regimen", "type": "DRUG" }, { "name": "BEACOPP regimen", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "procarbazine hydrochloride", "type": "DRUG" }, { "name": "vinblastine sulfate", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 371, "start_date": "2009-07", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-10-31T00:17:00.720Z", "location_count": 423, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 290 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00822120" }, { "nct_id": "NCT04360096", "title": "Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "SARS-CoV 2", "COVID", "ARDS", "ALI", "Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)", "Dyspnea" ], "interventions": [ { "name": "ZYESAMI™ (aviptadil acetate)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Nebulized administration of ZYESAMI™ or Placebo", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "APR Applied Pharma Research s.a.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 144, "start_date": "2021-02-15", "completion_date": "2021-12-31", "has_results": false, "last_update_posted_date": "2023-02-03", "last_synced_at": "2026-10-31T00:17:00.720Z", "location_count": 13, "location_summary": "Fullerton, California • Irvine, California • Miami, Florida + 10 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Winfield", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04360096" }, { "nct_id": "NCT03687827", "title": "A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin degludec", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 498, "start_date": "2018-10-02", "completion_date": "2019-12-27", "has_results": true, "last_update_posted_date": "2021-01-12", "last_synced_at": "2026-10-31T00:17:00.720Z", "location_count": 34, "location_summary": "Chandler, Arizona • Tucson, Arizona • Fresno, California + 28 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03687827" }, { "nct_id": "NCT02615873", "title": "A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "Accordion Pill™ Carbidopa/Levodopa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intec Pharma Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "30 Years to 100 Years" }, "enrollment_count": 460, "start_date": "2016-07", "completion_date": "2019-12", "has_results": false, "last_update_posted_date": "2018-08-14", "last_synced_at": "2026-10-31T00:17:00.720Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02615873" }, { "nct_id": "NCT02959983", "title": "Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Irritable Bowel Syndrome With Diarrhea" ], "interventions": [ { "name": "Eluxadoline", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 346, "start_date": "2016-10-25", "completion_date": "2018-01-22", "has_results": true, "last_update_posted_date": "2019-02-15", "last_synced_at": "2026-10-31T00:17:00.720Z", "location_count": 76, "location_summary": "Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 66 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Saraland", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Carmichael", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02959983" }, { "nct_id": "NCT04281472", "title": "A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)" ], "interventions": [ { "name": "efgartigimod PH20 SC in stage B", "type": "BIOLOGICAL" }, { "name": "placebo in stage B", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "argenx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 322, "start_date": "2020-04-15", "completion_date": "2023-05-11", "has_results": true, "last_update_posted_date": "2024-08-20", "last_synced_at": "2026-10-31T00:17:00.720Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Carlsbad", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04281472" }, { "nct_id": "NCT06305767", "title": "A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Intismeran autogene", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Enfortumab Vedotin", "type": "BIOLOGICAL" }, { "name": "Surgery (RC plus PLND)", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2024-03-28", "completion_date": "2031-10-20", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-10-31T00:17:00.720Z", "location_count": 10, "location_summary": "Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06305767" }, { "nct_id": "NCT03137992", "title": "Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Test Product (tiotropium bromide inhalation powder)", "type": "DRUG" }, { "name": "Reference Product (Spiriva®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lupin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 377, "start_date": "2017-11-21", "completion_date": "2018-04-30", "has_results": true, "last_update_posted_date": "2021-04-05", "last_synced_at": "2026-10-31T00:17:00.720Z", "location_count": 34, "location_summary": "Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03137992" } ] }